Upside case
Bull case
$131-39.0%
The bull case prices ALAB at 52x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
Analysis OverviewBuyUpdated May 1, 2026
Astera Labs, Inc. Common Stock (ALAB) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
15
analysts
12 bullish · 0 bearish · 15 covering ALAB
Strong Buy
0
Buy
12
Hold
3
Sell
0
Strong Sell
0
Consensus Target
$201
-6.0% vs today
Scenario Range
— – $131
Model bear to bull value window
Coverage
15
Published analyst ratings
Valuation Context
85.8x
Forward P/E · Market cap $36.4B
ALAB price targets
Three scenarios for where ALAB stock could go
Current
~$214
Confidence
51 / 100
Updated
May 1, 2026
Where we are now
Current · $214
Base
$214
Bull
$131
Market caseClosest to today
Base case
$214+0.0%
This is close to how the market is already pricing ALAB — at roughly 86x forward earnings. No dramatic re-rating needed, just steady execution on the core business.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Astera Labs, Inc. Common Stock
ALAB · NASDAQTechnologySemiconductorsDecember year-end
Astera Labs designs semiconductor connectivity solutions that enable high-performance cloud and AI infrastructure. It generates revenue primarily from selling its portfolio of data, network, and memory connectivity products — including both hardware chips and supporting software — to cloud service providers and data center operators. The company's competitive advantage lies in its software-defined architecture that allows customers to scale AI infrastructure efficiently, addressing critical bottlenecks in data movement.
Market Cap
$36.4B
Revenue TTM
$1.0B
Net Income TTM
$268M
Net Margin
26.7%
ALAB Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
100%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
+95.1%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Last 4 Quarters
EPS beats: 4 of 4Q2 2025
EPS
$0.33/$0.28
Revenue
$159M/$153M
Q3 2025
EPS
$0.44/$0.32
Revenue
$192M/$172M
Q4 2025
EPS
$0.49/$0.39
Revenue
$231M/$206M
Q1 2026
EPS
$0.58/$0.52
Revenue
$271M/$250M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q2 2025 | $0.33/$0.28 | +16.2% | $159M/$153M | +4.1% |
| Q3 2025 | $0.44/$0.32 | +35.8% | $192M/$172M | +11.3% |
| Q4 2025 | $0.49/$0.39 | +25.7% | $231M/$206M | +11.7% |
| Q1 2026 | $0.58/$0.52 | +12.4% | $271M/$250M | +8.4% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$1.4B
+35.4% YoY
FY2
$1.8B
+36.5% YoY
EPS Outlook
FY1
$2.40
+62.5% YoY
FY2
$3.39
+41.2% YoY
Trailing FCF (TTM)$343M
FCF Margin: 34.2%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
ALAB beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
ALAB Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $853M
Product Mix
Latest annual revenue by segment or product family
Reportable Segment
100.0%
YoY unavailable
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
SINGAPORE
32.5%
YoY unavailable
Tap, hover, or focus a slice to inspect segment detail.
Reportable Segment is the largest disclosed segment at 100.0% of FY 2025 revenue, with no year-over-year comparison yet.
SINGAPORE is the largest reported region at 32.5%, with no year-over-year comparison yet.
ALAB Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Overvalued
Fair value est. $96 — implies -52.5% from today's price.
Premium to Fair Value
52.5%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
ALAB
175.4x
vs
S&P 500
25.2x
+595% premium
vs Technology Trailing P/E
ALAB
175.4x
vs
Technology
27.5x
+538% premium
vs ALAB 5Y Avg P/E
Today
175.4x
vs
5Y Average
136.4x
+29% premium
Forward PE
85.8x
S&P 500
19.1x
+350%
Technology
21.7x
+295%
5Y Avg
—
—
Trailing PE
175.4x
S&P 500
25.2x
+595%
Technology
27.5x
+538%
5Y Avg
136.4x
+29%
PEG Ratio
—
S&P 500
1.75x
—
Technology
1.47x
—
5Y Avg
—
—
EV/EBITDA
201.4x
S&P 500
15.3x
+1220%
Technology
17.4x
+1059%
5Y Avg
—
—
Price/FCF
129.3x
S&P 500
21.3x
+506%
Technology
19.8x
+553%
5Y Avg
137.9x
-6%
Price/Sales
42.7x
S&P 500
3.1x
+1264%
Technology
2.4x
+1670%
5Y Avg
39.5x
+8%
Dividend Yield
—
S&P 500
1.88%
—
Technology
1.18%
—
5Y Avg
—
—
| Metric | ALAB | S&P 500 | Technology | 5Y Avg ALAB |
|---|---|---|---|---|
| Forward PE | 85.8x | 19.1x+350% | 21.7x+295% | — |
| Trailing PE | 175.4x | 25.2x+595% | 27.5x+538% | 136.4x+29% |
| PEG Ratio | — | 1.75x | 1.47x | — |
| EV/EBITDA | 201.4x | 15.3x+1220% | 17.4x+1059% | — |
| Price/FCF | 129.3x | 21.3x+506% | 19.8x+553% | 137.9x |
| Price/Sales | 42.7x | 3.1x+1264% | 2.4x+1670% | 39.5x |
| Dividend Yield | — | 1.88% | 1.18% | — |
ALAB trades above S&P 500 benchmarks on 5 of 5 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolALAB Financial Health
Verdict
Strong
ALAB generates $343M in free cash flow at a 34.2% margin — 12.3% ROIC signals a durable competitive advantage.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$1.0B
Revenue Growth
TTM vs prior year
+104.2%
Gross Margin
Gross profit as a share of revenue
76.0%
Operating Margin
Operating income divided by revenue
22.4%
Net Margin
Net income divided by revenue
26.7%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$1.48
Free Cash Flow (TTM)
Cash generation after capex
$343M
FCF Margin
FCF as share of revenue — the primary cash quality signal
34.2%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
12.3%
ROA
Return on assets, trailing twelve months
18.3%
Cash & Equivalents
Liquid assets on the balance sheet
$168M
Net Cash
Cash exceeds total debt — no net leverage
$132M
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE
Return on equity, trailing twelve months
20.3%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.0%
Dividend
—
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Current diluted share count
170M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageALAB Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Valuation Concerns
Astera Labs (ALAB) has an elevated valuation with a P/E ratio of 161.11, significantly higher than the market average of approximately 38.25. This overvaluation raises the risk of substantial price corrections if growth expectations are not consistently met.
High Risk
Delayed Revenue Streams
Management has indicated that UALink revenue is not expected until 2027, and optical revenue from the Xscale Photonics acquisition is projected for 2028-2029. This delay creates a risk that current valuations may be overly optimistic, pricing in significant revenue from these segments years in advance.
Medium
Insider Selling
There has been consistent and substantial insider selling by company executives and directors in recent months, without corresponding insider purchases. This trend raises concerns about management's long-term outlook and could negatively impact market sentiment.
Medium
Competition and Market Dynamics
Astera Labs faces increasing competition from emerging quantum computing vendors, which could pressure its growth and sustainability. The company's reliance on customer application-driven recurring revenue adds to the risk amid intensifying competitive dynamics.
Medium
Product and Technology Risks
The company is challenged by the development of quantum computing systems, with exposure to the emerging quantum solutions market posing risks. Additionally, a shift towards lower-margin module-based products is anticipated, potentially creating a 200 basis point gross margin headwind.
Lower
Analyst Sentiment Shifts
A recent 'Neutral' rating initiation from a major financial institution has tempered analyst sentiment, highlighting concerns about valuation and competition. This shift, along with insider selling and high valuation concerns, has likely contributed to recent price declines.
Lower
Macroeconomic Factors
Broader macroeconomic factors are cited as potential risks for ALAB, which could impact overall market performance and investor sentiment.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why ALAB Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Strategic Position in AI and Cloud
Astera Labs is a critical enabler of cloud and AI data center performance, benefiting from substantial capital expenditures by major tech companies like Amazon, Meta, and Google. This strategic position allows the company to capitalize on the growing demand for advanced connectivity solutions.
Strong Financial Performance and Growth
The company has demonstrated strong revenue growth, with significant year-over-year increases. It is forecasted to grow free cash flow substantially and maintains a robust two-year outlook for revenue and EBITDA growth.
Platform Transformation
Astera Labs is transitioning from a pure hardware growth story to a full-stack AI connectivity platform. This includes incorporating software-driven growth with its COSMOS telemetry suite and Scorpio-X fabric, enhancing its competitive edge.
Neutrality and Vendor Lock-in Avoidance
The company's neutral stance between NVIDIA's NVLink Fusion and the open UALink consortium positions it as an indispensable connectivity layer for hyperscalers. This strategy helps clients avoid vendor lock-in, making Astera Labs a preferred partner.
Positive Analyst Sentiment
A significant majority of analysts covering ALAB have a 'Buy' consensus rating, with many recommending a 'Strong Buy.' This positive sentiment reflects confidence in the company's growth prospects and market position.
Technical Strength
The stock has shown relative strength, breaking out to new all-time highs with increasing volume. This indicates accumulating buying pressure, suggesting strong investor interest and confidence in the company's future.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
ALAB Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$214.01
52W Range Position
75%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$63.40
+237.5% from the low
52-Week High
$262.90
-18.6% from the high
1 Month
+81.38%
3 Month
+26.00%
YTD
+19.2%
1 Year
+199.9%
3Y CAGR
+51.1%
5Y CAGR
+28.1%
10Y CAGR
+13.2%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
ALAB vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
85.8x
vs 69.2x median
+24% above peer median
Revenue Growth
+35.4%
vs +4.6% median
+668% above peer median
Net Margin
26.7%
vs 15.9% median
+68% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
ALA ALAB Astera Labs, Inc. Common Stock | $36.4B | 85.8x | +35.4% | 26.7% | Buy | -6.0% |
MRV MRVL Marvell Technology, Inc. | $149.1B | 44.9x | +29.9% | 32.6% | Buy | -24.8% |
CRU CRUS Cirrus Logic, Inc. | $8.6B | 18.5x | +4.6% | 20.7% | Buy | -13.5% |
MTS MTSI MACOM Technology Solutions Holdings, Inc. | $23.2B | 69.2x | +19.8% | 15.9% | Buy | -18.0% |
ALG ALGM Allegro MicroSystems, Inc. | $9.5B | 96.7x | -10.8% | -1.6% | Buy | -12.7% |
AXT AXTI AXT, Inc. | $4.6B | 3704.2x | -2.4% | -24.1% | Buy | -50.0% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
FAQ
7 questionsALAB Investor Questions
Common questions answered from live analyst data and company financials.
01Is Astera Labs, Inc. Common Stock (ALAB) stock a buy or sell in 2026?
Astera Labs, Inc. Common Stock (ALAB) is rated Buy by Wall Street analysts as of 2026. Of 15 analysts covering the stock, 12 rate it Buy or Strong Buy, 3 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $201, implying -6.0% from the current price of $214.
02What is the ALAB stock price target for 2026?
The Wall Street consensus price target for ALAB is $201 based on 15 analyst estimates. The high-end target is $250 (+16.8% from today), and the low-end target is $153 (-28.5%). The base case model target is $214.
03Is Astera Labs, Inc. Common Stock (ALAB) stock overvalued in 2026?
ALAB trades at 85.8x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals significantly overvalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Astera Labs, Inc. Common Stock (ALAB) stock in 2026?
The primary risks for ALAB in 2026 are: (1) Valuation Concerns — Astera Labs (ALAB) has an elevated valuation with a P/E ratio of 161. (2) Delayed Revenue Streams — Management has indicated that UALink revenue is not expected until 2027, and optical revenue from the Xscale Photonics acquisition is projected for 2028-2029. (3) Insider Selling — There has been consistent and substantial insider selling by company executives and directors in recent months, without corresponding insider purchases. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Astera Labs, Inc. Common Stock's revenue and earnings forecast?
Analyst consensus estimates ALAB will report consensus revenue of $1.4B (+35.4% year-over-year) and EPS of $2.40 (+62.5% year-over-year) for the upcoming fiscal year. The following year, analysts project $1.8B in revenue.
06When does Astera Labs, Inc. Common Stock (ALAB) report its next earnings?
A confirmed upcoming earnings date for ALAB is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Astera Labs, Inc. Common Stock generate?
Astera Labs, Inc. Common Stock (ALAB) generated $343M in free cash flow over the trailing twelve months — a free cash flow margin of 34.2%. ALAB returns capital to shareholders through and share repurchases ($0 TTM).